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Background: Evidence for the association between Human immunodeficiency virus infection and cervical cancer
has been contrasting, with some studies reporting increased risk of cervical cancer among HIV positive women
while others report no association. Similar evidence from Tanzania is scarce as HIV seroprevalence among cervical
cancer patients has not been rigorously evaluated. The purpose of this study was to determine the association
between HIV and tumor differentiation among patients with cervical cancer at Bugando Medical Centre and
Teaching Hospital in Mwanza, North-Western Tanzania.
Methods: This was a descriptive analytical study involving suspected cervical cancer patients seen at the
gynaecology outpatient clinic and in the gynaecological ward from November 2010 to March 2011.
Results: A total of 91 suspected cervical cancer patients were seen during the study period and 74 patients were
histologically confirmed with cervical cancer. The mean age of those confirmed of cervical cancer was
50.5 ± 12.5 years. Most patients (39 of the total 74–52.7%) were in early disease stages (stages IA-IIA). HIV infection
was diagnosed in 22 (29.7%) patients. On average, HIV positive women with early cervical cancer disease had
significantly more CD4+ cells than those with advanced disease (385.8 ± 170.4 95% CI 354.8-516.7 and 266.2 ± 87.5,
95% CI 213.3-319.0 respectively p = 0.042). In a binary logistic regression model, factors associated with HIV
seropositivity were ever use of hormonal contraception (OR 5.79 95% CI 1.99-16.83 p = 0.001), aged over 50 years
(OR 0.09 95% CI 0.02-0.36 p = 0.001), previous history of STI (OR 3.43 95% CI 1.10-10.80 p = 0.035) and multiple
sexual partners OR 5.56 95% CI 1.18-26.25 p = 0.030). Of these factors, only ever use of hormonal contraception was
associated with tumor cell differentiation (OR 0.16 95% CI 0.06-0.49 p = 0.001). HIV seropositivity was weakly
associated with tumor cell differentiation in an unadjusted analysis (OR 0.21 95% CI 0.04-1.02 p = 0.053), but strong
evidence for the association was found after adjusting for ever use of hormonal contraception with approximately
six times more likelihood of HIV infection among women with poorly differentiated tumor cells compared to those
with moderately and well differentiated cells (OR 5.62 95% CI 1.76-17.94 p = 0.004).
Conclusion: Results from this study setting suggest that HIV is common among cervical cancer patients and that
HIV seropositivity may be associated with poor tumour differentiation. Larger studies in this and similar settings
with high HIV prevalence and high burden of cervical cancer are required to document this relationship.
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Cancer of the cervix is the second most common cancer
among women worldwide with an estimate of 529,409
new cases and 274,883 deaths each year [1-4]. About
80% of cervical cancer cases occur in developing coun-
tries. The age-standardized incidence rate in Sub-
Saharan Africa is 30–67 per 100,000 which is two to ten
times higher than that in developed countries [3]. In
Tanzania, cervical cancer is the leading malignancy
among women [1]. The incidence rate of the disease in
the country is estimated at 40.6 per 100,000 women with
approximately 7515 new cases annually [1,5].
The majority of cases are squamous cell carcinoma
(85%) and adenocarcinomas (10-12%). Several other
types of carcinoma such as adenosquamous carcinoma,
adenoid cystic carcinoma, small cell carcinoma and
mucinous cancers make up the remaining 3-5% of all
cases [1].
The etiology and natural history of cervical cancer is
well understood. The proximate causative factor is infec-
tion with the high-risk HPV types including 16, 18, 33 &
45. The high-risk HPV types 16 and 18 are the most fre-
quent types and cause about 70% of cancer of cervix
worldwide [6,7]. Other proposed independent risk fac-
tors for developing cervical cancer include long term use
of oral contraceptives, smoking, age at menarche, age at
menopause and behaviour which exposes one to have
HPV infection such as early sexual debut, increased
number of lifetime sexual partners and history of sexu-
ally transmitted diseases [6,7].
Cervical cancer commonly affects women of middle
or older age, but with era of HIV/AIDS it may be
diagnosed in any reproductive age women as HIV in-
fection appears to enhance HPV proliferation [8,9]; al-
though the mechanism by which HIV increases risk
of cervical cancer is not clearly understood. It is sug-
gested that HIV induced immunosuppression reduces
the ability of the body’s immune system to control
the expression of HPV and the production of HPV
oncoproteins E6 and E7. The risk appears to be asso-
ciated with increased HPV persistence and reactiva-
tion that may result from immunosuppression related
to HIV. The risk is greater in women with low CD4+
counts, especially those with less than 200 cells/μL
and in those with high plasma HIV-RNA levels. Fur-
ther; HIV infection is associated with high risk HPV
types known to cause invasive cervical cancer [9-11].
Specifically for Sub-Saharan Africa, more prevalent
high-risk and diverse HPV types linked to HIV may
exist than elsewhere [8], thus the observed
association.
Worldwide, cancer of the cervix has been included
as one of the AIDS-defining illnesses and an
increased risk of invasive cervical cancer among HIVpositive women is documented [4,12,13]. Nevertheless,
cervical cancer as a leading malignancy among
women not withstanding [1], the magnitude of HIV
infection among cervical cancer patients is still not
well known in most low-resourced countries bur-
dened with high levels of HIV infection and cervical
cancer. In Tanzania, for example, women with cer-
vical cancer are not routinely tested for HIV. In
addition, lack of a cancer registry in the country does
not allow retrospective analysis for factors associated
with various cancers, including HIV. Thus, studies on
factors associated with cancers in a clinical setting re-
main the best opportunity to document this relation-
ship, albeit at limited magnitude. We conducted a
descriptive and analytical study to document the asso-
ciation between HIV infection and cervical cancer cell
differentiation at Bugando Medical Centre- a tertiary
referral and teaching hospital in Mwanza, North-west
Tanzania.
Methods
This was a descriptive analytical study involving sus-
pected cervical cancer patients. The study was carried
out in the gynecological outpatient clinic and
gynecological ward between November 2010 and March
2011. Bugando Medical Centre serves about 13 million
people from six regions of Mwanza, Kagera, Shinyanga,
Mara, Kigoma and Tabora in the Lake Zone. The Hos-
pital has a bed capacity of approximately 800. It also
has a well equipped pathology laboratory manned by
two pathologists. About 3–4 women with suspected
cancerous lesion of the cervix are seen weekly at the
hospital for investigation and initial care before radio-
therapy. Approximately 389 cases of cervical cancer are
seen yearly [14].
The study population included all consecutive women
with suspicious cervical cancer lesions who were either
admitted in gynecological wards or seen at the
gynecological outpatient clinic. Women were excluded if
they were unconscious without next of kin to consent
on their behalf.
Invasive cervical cancer was diagnosed histologically if
the cancer had made stromal invasion of at least 3 mm
and 7 mm in depth and width respectively. Suspected
cervical cancer patients were those with contact vaginal
bleeding/postmenopausal bleeding, abnormal vaginal
discharge, fecal/urine incontinence and pelvic/loin pain
with or without visible cervical lesion on speculum
examination. HIV infected person was defined as a per-
son who was HIV seropositive as per recommended
Tanzanian National AIDS Control Programme HIV
diagnostic testing algorithm [15]. Tumor cell differenti-
ation was defined as the extent to which the cancer cells
resembled comparable normal cells, and was categorized
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poorly differentiated tumours.
Data were collected using pre-tested structured ques-
tionnaires. Information collected through participants
interview included demographic characteristics (age,
marital status, parity, educational level, occupation, re-
gion of residence), parity of the participant, age at first
pregnancy, age at sexual debut, use of modern contra-
ceptives and smoking. In addition, blood was taken
from each participant for laboratory investigations:
complete blood count, serum Creatinine level, and HIV
antibody test. Examination under anaesthesia for disease
staging was done as well as taking a punch biopsy from
cervical lesion for histological examination. Biopsy was
preserved in 10% formalin. Histological examination
was done by light microscopy under Haematoxylin and
Eosin stain.
Pre and post-test counseling and examination for
HIV followed the available national guidelines [15].
SD-Bioline (Standard Diagnostics, Inc. Kyonggi-do,
Korea) was used for testing HIV among patient with
cancer of the cervix and positive results were further
confirmed by Determine HIV 1&2 serum/plasma
assays (Abbott Diagnostic Division, Tokyo Japan). Un-
determined results were further tested using Uni-Gold
Recombigen™ HIV rapid test as per existing nation al-
gorithm for HIV testing. CD4+ count estimation was
done using CD4+ analyzer-Facs counts (BD Biosystem
USA) as per manufacturer’s protocol. The test is rou-
tinely done to all newly diagnosed HIV positive
patients to determine their eligibility into treatment.
Chest x-rays and abdominal/pelvic ultrasound were
taken for the purpose of staging.
Collected data were entered into EpiData version 3.1,
and then exported into STATA version 11 for cleaning,
consistency checks and analysis. A t-test statistic was
used to analyze continuous data into means, standard
deviations and confidence intervals. Categorical vari-
ables were summarized into proportions and compared
using Chi-square statistical test and Odds ratios. Bin-
ary logistic regression was done to determine risk fac-
tors for cervical cancer. Factors with p-value less than
or equal to 0.05 were retained for multivariate logistic
regression to calculate their odd ratios and confidence
intervals. Respective p-values at 95% confidence level
are also reported.
Ethical review and approval was sought and
obtained from Joint Weill Bugando University and
Bugando Hospital ethical, research and publication
committee. Informed consent was requested and
obtained from all participants in Kiswahili language.
HIV-positive women were referred to the HIV/AIDS
care and treatment unit at the hospital for further
management.Results
A total number of 106 patients with a suspected clinical
diagnosis of cervical cancer were seen in the
Gynecological ward/clinic at Bugando Medical Centre
during the study period. Of these, 15 patients were
excluded from the study (8 patients did not consent for
HIV testing and 7 patients had communication pro-
blems). Therefore a total of 91 patients were recruited in
the study.
Of the 91 patients with suspicious cervical lesions, 74
(81.3%) had histological confirmation of cervical cancer,
and thus included in the analysis. The mean age of parti-
cipants with cervical cancer was 50.5 ± 12.5 years (range
29–85 years). The level of education among study parti-
cipants was low, with almost half (52.7%) of all partici-
pants having no formal education and just 2(2.7%)
educated beyond primary education. The majority 58
(78.3%) were peasant farmers (Table 1).
Of all cervical cancer patients, 44 (56.4%) were already
married by the age of 18 years and 51(68.9%) of partici-
pants had delivered more than five children in their life-
time. The median parity was 7.0 (not shown in Table 1).
History of a sexual transmitted infection was reported in
15 (20.3%) participants. Ever use of hormonal contracep-
tion was reported in 25 (33.8%) of the study participants,
although it was not possible to accurately record the
duration of use (Table 1).
Of the total 74 cervical cancer confirmed cases, 39
patients (52.7%) were in early stages of the disease: 24
(32.4%) in stage IB and 15 (20.3%) in stage IIA). Of
the remaining 35 patients with late stage disease, 11
(14.9%) were in stage IIB, six (8.1%) in stage IIIA, ten
patients (13.5%) in stage IIIB and eight patients
(10.8%) in stage IVA (Table 2). Abnormal vaginal dis-
charge and contact vaginal bleeding were the most
common clinical presentations among participants
reported by 63 (85.1%) and 61 (82.4% patients respect-
ively. Thirty six percent of the participants had post-
menopausal bleeding; approximately 43 (58.1%) had
ulcerative types of cervical lesions and 34 (45.9%) had
fungating lesions (not shown in tables).
Squamous cell carcinoma was the commonest type
of cancer comprising of 69 (93.2%) of the total 74 par-
ticipants. Other histological types of cervical cancer
were 3 (4.1%) adenocarcinoma and 2 (2.7%) small cell
carcinoma. Overall, HIV seropositivity among partici-
pants with cervical cancer was 29.7%. The level of
HIV seroprevalence in the various diseases stages were
22.7% (5 of the 24 participants in stage 1b), 26.7%
(four of the fifteen participants in stage IIa), 36.4%
(four of the eleven participants in stage IIb) and 50.5%
(three of the six in stage IIIa); 40.0% (four of the ten
patients in stage IIIb and two of the total eight
patients in stage IVa (25.0%).
Table 1 Socio-demographic and Reproductive characteristics of the study population
Characteristics HIV+ (n = 22) HIV- (n = 52) Total (n = 74)
Number Mean± SD Number Mean± SD Number Mean± SD
Age in years 40.2 ± 8.6 54.9 ± 11.4 50.5 ± 12.5
Age group
≤35 7 (31.8) 1 (1.9) 8 (10.8)
36-45 10 (45.5) 9 (17.3) 19 (25.7)
46-55 3 (13.6) 18 (34.6) 21 (28.4)
56+ 2 (9.1) 24 (46.2) 26 (35.1)
Education level
No formal education 5 (22.7) 34 (65.4) 39 (52.7)
Primary education 16 (72.7) 17 (32.7) 33 (44.6)
Secondary education 1 (4.5) 1 (1.9) 2 (2.7)
Marital status
Married 11 (50.0) 32 (61.5) 43 (58.1)
Widow/Separated 11 (50.0) 20 (38.5) 31 (41.9)
Occupation
Peasant/farmer 13 (59.1) 45 (86.5) 58 (78.3)
Housewife 3 (13.6) 0 (0) 3 (4.1)
Professional salaried job 1 (4.5) 2 (3.8) 3 (4.1)
Petty trader 5 (22.7) 5 (9.6) 10 (13.5)
Area of residence
Mwanza 13 (59.1) 23 (44.2) 36 (48.6
Mara 4 (18.2) 11 (21.2) 15 (20.3)
Shinyanga 4 (18.2) 11 (21.2) 15 (20.3)
Others 1 (4.5) 7 (13.5) 8 (10.8)
Age at Marriage
<18 years 10 (45.5) 31 (59.6) 41 (54.4)
≥18 years 12 (54.5) 21 (40.4) 33 (45.6)
Parity
≤1 2 (9.1) 1 (1.9) 3 (4.1)
2-5 2 (9.1) 13 (25.0) 20 (27.0)
>5 18 (81.8) 38 (73.1) 51 (68.9)
History of STIs
Yes 8 (36.4) 7 (13.5) 15 (20.3)
No 14 (63.6) 45 (86.5) 59 (79.7)
Lifetime sexual partners
1 2 (9.1) 18 (34.6) 20 (27.0)
>1 20 (90.9) 34 (65.4) 54 (73.9)
Contraceptive use
None 8 (36.4) 41 (78.8) 49 (66.2)
Pills 9 (40.9) 7 (13.5) 16 (21.6)
Barrier 0 (0) 1 (1.9) 1 (1.4)
Implants 3 (13.6) 2 (3.8) 5 (6.8)
Depo provera 2 (9.1) 1 (1.9) 3 (4.0)
Note: Number in brackets denotes respective percentages.
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Table 2 HIV seropositivity in relation to some selected
participant characteristics (N= 74)
Characteristic HIV serostatus Total p-value
Positive Negative
Age group
≤50 years 19 (50.0) 19 (50.0) 38 (100.0) <0.001 (Pearson)*
>50 years 3 (8.3) 33 (91.7) 36 (100.0)
Sub-total 22 (29.7) 52 (70.3) 74 (100.0)
Clinical stage
Stage IB 5 (20.8) 19 (79.2) 24 (100.0)
Stage IIA 4 (26.7) 11 (73.3) 15 (100.0)
Stage IIB 4 (36.4) 7 (63.6) 11 (100.0)
Stage IIIA 3 (50.0) 3 (50.0) 6 (100.0)
Stage IIIB 4 (40.0) 6 (60.0) 10 (100.0)
Stage IVA 2 (25.0) 6 (75.0) 8 (100.0)
Total 22 (29.7) 52 (70.3) 74 (100.0)
Stage classification
Early stage (IA-IIA) 9 (23.1) 30 (76.6) 39 (100.0) 0.186 (Pearson)**
Advanced stage
(IIB-IVB)
13 (37.1) 22 (62.9) 35 (100.0)
Total 22 (29.7) 52 (70.3) 74 (100.0)
Tumor cell
differentiation
Well 12 (52.2) 11 (47.8) 23 (100.0) 0.006 (exact)***
Moderate 8 (25.8) 23 (74.4) 31 (100.0)
Poor 2 (11.1) 16 (88.9) 18 (100.0)
Total 22 (30.6) 50 (69.4) 72 (100.0)****
Note: Number in brackets denotes percentages.
*p-value comparing HIV seropositivity between participants aged≤ 50 years
versus those aged over.
**p-value comparing HIV seropositivity between women with early versus late
stage disease.
***p-value comparing participants with well differentiated and combined
moderately and poorly differentiated tumor cells.
****Two patients had small cell carcinoma whose cellular differentiation could
not be determined.
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thirty eight patients who were aged 50 years and less.
Three of the thirty six patients (8.3%) aged over 50 years
were HIV positive compared to nineteen of the thirty
eight patients (50.0%) aged 50 years and less (p < 0.001,
Table 2). There were 23 patients with well differentiated
tumor cells (31.9%) compared to 49 patients with mod-
erately and poorly differentiated cancer cells. Of the
total 23 patients 12 (52.2%) were HIV+ compared to
ten patients among the 49 patients (20.4%) with moder-
ately and poorly differentiated tumor cells and the dif-
ference of seropositivity was statistically significant
(p = 0.006).
The mean CD4+ count of the 22 HIV positive partici-
pants was 315.0 ± 138.0. Overall, 68.2% of all participantshad CD4+ counts of ≤ 350. On average, HIV+ patients
with early stage disease (stage IA-IIA) had more CD4+
count than those with advanced disease (Stage IIB-IVB)
(mean 385.8 ± 170.4; 95% CI 354.8-516.7 and 266.2 ± 87.5;
95% CI 213.3-319.0 respectively, p = 0.042) (Table 3). In
contrast, the average CD4+ count of the 12 patients with
well differentiated tumor cells did not differ significantly
from the combined ten patients with moderately and
poorly differentiated tumor cells (mean CD4+ count
318± 148.0, 95% CI 224.8-412.9 versus 310.6 ± 132.8, 95%
CI 215.6-405.6; p = 0.893 respectively).
Factors associated with HIV seropositivity were explored
in a binary logistic regression analysis (Table 4). History of
STI, ever use of modern contraception, aged over 50 years
and previous history of multiple sexual partners were sig-
nificantly associated with HIV seropositivity. Except for a
strong evidence to suggest that ever use of modern
contraception was associated with cancer cell differenti-
ation (comparing poorly differentiated tumor cells and
combined well and moderately differentiated cells
patients), there was no evidence to suggest an association
between cancer cell differentiation and history of STI, age
of more than 50 years or history of lifetime multiple sexual
partners (Table 4).
In unadjusted binary logistic regression model com-
paring poorly differentiated tumor cell patients versus
combined well and moderately differentiated tumor cell
patients, there was weak evidence to suggest an associ-
ation between HIV seropositivity and cancer cell differ-
entiation (OR 0.21 95% CI 0.04-1.02, p = 0.053). Ever use
of hormonal contraception- a factor associated with both
HIV and cancer cell differentiation was adjusted for in a
multivariate logistic regression model. There was strong
evidence to suggest that HIV seropositivity was asso-
ciated with cancer cellular differentiation after the adjust-
ment (OR 5.62 95%CI 1.76-17.94, p = 0.004) (Table 4),
indicating an almost six fold likelihood of HIV seropositiv-
ity among women with poorly differentiated tumor cells
compared to those with well and moderately differentiated
cells.
Discussion
Results from this study suggest that women with poorly
differentiated cancer cells are more likely to be HIV
positive than those with well and moderately differen-
tiated cell types, especially after adjusting for ever use of
hormonal contraception. The finding of almost a six
times more likelihood of HIV infection among these
women suggests an additional risk besides the known
poorer prognosis [16]. An association of poorly differen-
tiated cervical tumor cells and HIV has been reported in
a study done in Kenya [16].
In this study; HIV seropositivity among participants
with cervical cancer was 29.7%. The majority of the
Table 3 CD4+ distribution, level of differentiation and Cancer stage among HIV+participants (n = 22)





Well 8 (66.7) 4 (33.3) 12 (100.0)
Moderate 5 (62.5) 3 (37.5) 8 (100.0)
Poor 2 (100.0) 0 (0) 2 (100.0)
Total 15 (68.2) 7 (31.8) 22 (100.0)
Overall CD4 count n = 22 315.0 ± 138.0
Well differentiated n= 12 318.8 ± 148.0
Moderately and poorly differentiated n= 10 310± 132.8 0.893*
Cancer stage
Early stage ( IA-IIA) 5 (55.6) 4 (44.4) 9 (100.0) 385.8 ± 170.4 354.8-516.7 0.042**
Late stage (IIB-IVB) 10 (76.9) 3 (23.1) 13 (100.0) 266.2 ± 87.5 213.3-319.0
Total 15 (68.2) 7 (31.8) 22 (100.0) 0.290 (Pearson)***
Note: Number in brackets denotes%.
* p-value from a t-test statistic comparing the mean CD4+ count between well differentiated and
moderate and poorly differentiated tumor cell patients.
** p-value from a t-test statistic comparing the mean CD4+ count between early and late stage disease.
***p-value comparing women with CD4+ count ≤350/μL in early and late stage diseases.
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less than 50 years, and the finding is similar to reports
from other studies [5,9]. The high prevalence of cervical
cancer in participants aged less than 50 years in this
study may be influenced by the high HIV seropositivity
in this group, as HIV has been shown to cause rapidTable 4 Logistic regression model for factors associated with
Factor
1: binary analysis
Factors associated with cell differentiation
Previous history of STI versus none
History of modern contraceptive use versus never used
Age at first delivery before 18 years versus≥ 18 years
History of multiple sexual partners in one’s lifetime versus none
Age> 50 years versus≤ 50 years
Factors associated with HIV serostatus
Previous history of STI versus none
History of modern contraceptive use versus never used
Age at first delivery before 18 years versus ≥18 years
History of multiple sexual partners in one’s lifetime versus none
Age> 50 years versus ≤50 years
2: HIV and cancer cellular differentiation n= 72
Binary (unadjusted) logistic regression: HIV and cancer cell
differentiation (poorly differentiated versus well and moderately differentiated
Multivariate (adjusted) logistic regression: HIV and cancer cell
differentiation (poorly differentiated versus well and moderately differentiated
* adjusted for ever used modern contraception or not.progression of cervical cancer [8-11]. Nevertheless, the
nature of the study does not allow causal inferences.
Most of the HIV positive patients (68.2%) had a CD4+
count of less than 350cells/μl indicating the need for
HIV screening of all cervical cancer patients so that ap-
propriate treatment is initiated concurrent with cervicalpoor cell differentiation and HIV seropositivity
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was seen more often among women with advanced cer-
vical cancer than those who had more counts although
the difference was not statistically significant. This is
contrary to other study findings in which a low CD4+
count was associated with advanced cervical cancer
stages at presentation [8,10,11].The difference may be
attributed to the small sample size in our study.
The histopathology findings of squamous cell carcin-
oma as the most common type of cervical cancer in our
study is similar to studies done in Kenya, Uganda and
South Africa in which as high as 80% of cases had squa-
mous cell carcinoma [13,16-18]. In contrast, the finding
of non-squamous cervical cancer in this study of just
8.7% is lower than the 11% reported in Nigeria [19].
The limitations of this study are worth mentioning.
The sample size of this study was small and the nature
of the study does not allow causal inferences. Partici-
pants were women who sought care at a health unit dur-
ing the study period. Although we believe that their
characteristics, including the outcomes of interest may
not differ from the population of women with similar
conditions who seek care at the hospital annually, the
findings may not be extrapolated to the pattern of the
disease countrywide.
Conclusion
Results from this study suggest that HIV seropositivity is
associated with cervical cancer cell differentiation and
that HIV co-infected women present with relatively low
CD4+ count. More studies are needed in this and similar
settings to reliably document this relationship so that
clear guidelines for the management of cervical cancer
patients co-infected with HIV are developed. In the in-
terim, HIV screening should be encouraged among all
cervical cancer patients to enable timely linkage to ap-
propriate care, treatment and support.
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